Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GZMB | P10144 | 14/20 | 0.39 |
| ▸ | XIAP | P98170 | 1/20 | 0.37 |
| ▸ | CASP3 | P42574 | 3/20 | 0.37 |
| ▸ | CASP2 | P42575 | 3/20 | 0.37 |
| ▸ | NAALAD2 | Q9Y3Q0 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21750830 | 1.00 | GZMB (0.39) | GZMBXIAPCASP3CASP2NAALAD2 | |
| SCHEMBL17491005 | 0.94 | GZMB (0.43) | GZMB | |
| SCHEMBL20845526 | 0.94 | GZMB (0.43) | GZMB | |
| SCHEMBL19181255 | 0.94 | GZMB (0.43) | GZMB | |
| SCHEMBL19182502 | 0.94 | GZMB (0.43) | GZMB | |
| SCHEMBL19180841 | 0.94 | GZMB (0.39) | GZMBXIAPNAALAD2 | |
| SCHEMBL21750840 | 0.94 | GZMB (0.39) | GZMBXIAPNAALAD2 | |
| SCHEMBL17491003 | 0.94 | GZMB (0.39) | GZMBXIAPNAALAD2 | |
| SCHEMBL20845525 | 0.93 | GZMB (0.38) | GZMBXIAPCASP3CASP2 | |
| SCHEMBL17490991 | 0.93 | GZMB (0.38) | GZMBXIAPCASP3CASP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10246487-B2 | Azaindoline compounds as granzyme B inhibitors | VIDA THERAPEUTICS INC. (CA) | 2019-04-02 | — | — | US | claimed |
| US-20200062803-A1 | AZAINDOLINE COMPOUNDS AS GRANZYME B INHIBITORS | VIDA THERAPEUTICS INC. (CA) | 2020-02-27 | — | — | US | disclosed |
| US-20200062803-A1 | AZAINDOLINE COMPOUNDS AS GRANZYME B INHIBITORS | VIDA THERAPEUTICS INC. (CA) | 2020-02-27 | — | — | US | disclosed |
| US-10246487-B2 | Azaindoline compounds as granzyme B inhibitors | VIDA THERAPEUTICS INC. (CA) | 2019-04-02 | — | — | US | disclosed |
| US-10246487-B2 | Azaindoline compounds as granzyme B inhibitors | VIDA THERAPEUTICS INC. (CA) | 2019-04-02 | — | — | US | disclosed |
| US-20170218014-A1 | AZAINDOLINE COMPOUNDS AS GRANZYME B INHIBITORS | VIDA THERAPEUTICS INC. (CA) | 2017-08-03 | — | — | US | disclosed |
| US-20170218014-A1 | AZAINDOLINE COMPOUNDS AS GRANZYME B INHIBITORS | VIDA THERAPEUTICS INC. (CA) | 2017-08-03 | — | — | US | disclosed |
| US-20170218014-A1 | AZAINDOLINE COMPOUNDS AS GRANZYME B INHIBITORS | VIDA THERAPEUTICS INC. (CA) | 2017-08-03 | — | — | US | disclosed |
| WO-2016015159-A1 | AZAINDOLINE COMPOUNDS AS GRANZYME B INHIBITORS | VIDA THERAPEUTICS, INC. (CA) | 2016-02-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170218014-A1 | AZAINDOLINE COMPOUNDS AS GRANZYME B INHIBITORS | GZMB, DNASE1L3, DNASE1 | GZMB 1/4885XIAP 137/4885CASP3 86/4885 |
| US-10246487-B2 | Azaindoline compounds as granzyme B inhibitors | GZMB, DNASE1L3, DNASE1 | GZMB 1/4885XIAP 137/4885CASP3 86/4885 |
| US-20200062803-A1 | AZAINDOLINE COMPOUNDS AS GRANZYME B INHIBITORS | GZMB, DNASE1L3, DNASE1 | GZMB 1/4885XIAP 137/4885CASP3 86/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.